Valacyclovir hydrochloride

Quick links to important sections

Valacyclovir hydrochloride

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valacyclovir hydrochloride

Valacyclovir hydrochloride is a synthetic prescription medicine used to manage infections caused by the herpesvirus family. It is a single-ingredient product administered by the oral route, typically available as a tablet or as an extemporaneously prepared oral suspension for specific patient needs.

Property Description
Active Ingredient Valacyclovir
Form Oral tablet, Oral suspension
Pharmacological Class Antiviral agent, Nucleoside analogue
Common Use Suppression of herpesvirus infections
Origin Synthetic compound (derivative/prodrug)

What Type of Medicine is Valacyclovir Hydrochloride?

Valacyclovir hydrochloride is formally classified as an antiviral agent, belonging to the high-level pharmacological class of nucleoside analogues. This medicine is a synthetic compound derived from the established antiviral drug, acyclovir, which itself is a guanine nucleoside analogue. The compound is characterized by its selective activity against viral-infected cells. The structural modification that incorporates an L-valine ester enables the drug to function as a prodrug.

Composition and the Prodrug Concept

The essential active ingredient is Valacyclovir, which operates as a prodrug—an inactive compound that becomes therapeutic only after rapid metabolism within the body into its active moiety, acyclovir. This specific molecular structure is engineered to significantly improve the medicine's absorption from the digestive tract, a differentiating factor that results in enhanced oral bioavailability. This improved property represents a therapeutic advantage, ensuring that a consistent and substantial concentration of the active component reaches the bloodstream.

What is the General Purpose of Valacyclovir?

The overarching purpose of Valacyclovir is to limit the progression of susceptible viral illnesses by directly interfering with their ability to spread and multiply. The drug's active form works by inhibiting the virus’s ability to copy its genetic material (DNA), thereby suppressing viral activity. Due to its improved absorption, Valacyclovir represents an advance in antiherpes drug therapy, providing an effective, first-line treatment option for many patients.

Regulatory References

  1. NIH LiverTox (Valacyclovir Monograph)

What side effects are possible with Valacyclovir hydrochloride?

Possible Side Effects and Safety Information

The safety profile for Valacyclovir hydrochloride is defined by regulatory authorities based on the frequency and system-organ class affected by reported adverse reactions. This classification details both common events and serious, clinically significant risks.


Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions are classified as Very Common or Common in regulatory labeling:

  • Very Common / Most Common: These include Headache and Nausea, which are the most widely reported reactions across clinical data.
  • Common: Adverse reactions observed in this range include Dizziness, Vomiting, Diarrhea, Abdominal pain, Rash, and Pruritus (itching).

System-Organ Class and Serious Risks

Adverse reactions are formally grouped by the body system affected, with common effects observed across Gastrointestinal and Nervous System disorders. The official labeling documents specific, serious adverse reactions that warrant attention:

  • Acute Renal Failure: This is a documented risk, particularly in individuals with pre-existing renal impairment or those receiving other drugs known to affect the kidneys.
  • Severe Central Nervous System (CNS) Reactions: Serious events such as Confusion, Agitation, Hallucinations, and Encephalopathy are listed. These CNS reactions are generally noted to be reversible upon treatment discontinuation, but are a greater risk in older adults and those with reduced kidney function.
  • TTP/HUS: Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS) are rare, severe blood disorders observed primarily in certain highly immunocompromised patients receiving high doses of the medication.

Population-Specific Safety Considerations

The risk profile is officially noted to be increased for certain patient groups. Older adults and patients with underlying renal impairment are documented as being at a higher likelihood of experiencing Acute Renal Failure and severe CNS adverse reactions. Adequate fluid intake is also advised in official documents for patients at risk of dehydration.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe specific clinical manifestations associated with Valacyclovir hydrochloride overdose, necessitating immediate medical attention. Overdose frequently affects the Central Nervous System (CNS) and the renal system, sometimes leading to severe outcomes.

Documented Manifestations and Severe Outcomes

Overdose presentations officially documented in regulatory sources include severe CNS effects such as confusion, hallucinations, agitation, and the risk of progression to seizures and coma. A critical outcome is acute renal failure, indicated by elevated creatinine and blood urea levels, which is often associated with high systemic exposure.

Potentially life-threatening complications, notably Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS), have been reported in severely immunocompromised patients receiving high doses.

Population Risks and Emergency Action

Elderly patients and individuals with pre-existing renal impairment are officially noted as being at increased risk for CNS adverse reactions and acute renal failure following overdose. The official regulatory guidance mandates that patients seek emergency medical attention or call a Poison Help line immediately for any suspected overdose.

Treatment for overdose is officially defined as symptomatic and supportive. Regulatory labeling notes that the active metabolite, acyclovir, is removable by hemodialysis in cases of symptomatic overdose or acute renal failure. No specific antidote is known.

Therapeutic Uses of Valacyclovir hydrochloride

What Valacyclovir hydrochloride Treats: Main Uses and Benefits

Valacyclovir hydrochloride is commonly used in conditions characterized by periods of heightened symptoms caused by herpesviruses. This medicine is generally applied across domains where additional symptomatic support is needed, and contributes to easing the overall symptom load.


The medication is applied in addressing acute episodes of shingles (Herpes Zoster), cold sores (Herpes Labialis), and initial or recurrent genital herpes. It is also considered relevant in clinical settings for treating chickenpox in specific pediatric patient groups. It is also relevant when supportive symptom management is appropriate, including assisting with reduction of viral transmission risk to a partner.

Therapeutic Support and Comfort

This medicine helps address symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort like pain, burning, tingling, and the visible manifestation of sores and blisters. This supports the patient during difficult episodes by easing distress and is commonly used to help with the resolution of active lesions. It is also applied across domains where additional symptomatic support is needed for long-term suppression of frequent recurrences.

This approach is applied in situations where supportive symptom management is appropriate to assist with coping more steadily with difficult episodes.


Quick Fact: Relief for Neurocutaneous Discomfort

This medication is generally relevant for easing discomfort associated with symptoms of increased neurological or muscular activity (pain, tingling, burning) that accompany the visible rash or lesions caused by the viral infection.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Valacyclovir hydrochloride eligibility is determined by specific regulatory criteria concerning age, immune status, and renal function.

Populations for Whom Use is Restricted or Contraindicated

Classification Official Regulatory Rule
Contraindicated Patients with a known hypersensitivity to valacyclovir, acyclovir, or any component of the formulation must not use this medicine.
Conditional Use Patients with impaired renal function require special caution and a review of the dosage due to the drug’s elimination via the kidneys. Elderly patients are also subject to this review as they may have reduced kidney function.
Limited Eligibility Severely immunocompromised patients, including certain transplant recipients, are associated with a higher risk of severe adverse events. Use for suppressive therapy in HIV-infected adults is limited to those with a CD4+ cell count ge 100 cells/ mm^3.

Age-Related Eligibility

The medicine is generally established for use in immunocompetent adults for all labeled indications. Specific pediatric eligibility applies:

  • Cold sores (Herpes Labialis): Use is established in patients ge 12 years of age.
  • Chickenpox: Use is established in immunocompetent patients 2 to <18 years of age.

Conversely, efficacy and safety are not established for treating genital herpes or herpes zoster in patients under 18 years of age, nor for cold sores in patients under 12 years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for valacyclovir hydrochloride primarily details interactions that affect the renal clearance of its active metabolite, acyclovir, and pharmacodynamic interactions that heighten organ-specific risks.

Documented Pharmacokinetic Interactions

The most significant documented interactions occur with medicines that compete for the active tubular secretion pathway in the kidneys, which is the primary route of elimination for acyclovir.

Interacting Substance Official Interaction Outcome Effect on Exposure
Probenecid Reduces the renal clearance of acyclovir Increases acyclovir AUC
Cimetidine Reduces the renal clearance of acyclovir Increases acyclovir AUC
Probenecid and Cimetidine (combined) Results in an additive reduction in renal clearance More pronounced increase in acyclovir AUC

These exposure-modifying effects are not typically considered clinically significant in individuals with normal renal function, but the risk is formally noted as being heightened in elderly patients and those with underlying renal impairment.

Pharmacodynamic and Other Interactions

Co-administration with other nephrotoxic drugs is associated with an officially documented, heightened risk of acute renal failure. The official labeling confirms that the pharmacokinetics of acyclovir are not affected by co-administration with food or single doses of Antacids.

Mechanism of Action

The drug's action is reliant on its conversion to the active antiviral component, Acyclovir, which initiates a highly selective biochemical cascade within virus-infected cells. The mechanism is rooted in its high degree of biochemical selectivity, as the drug requires the virus's own enzyme, Viral Thymidine Kinase (TK), for its initial phosphorylation and activation. This initial step occurs almost exclusively inside the host cells where the virus is actively replicating, demonstrating minimal activity in uninfected host cells. Once fully activated to Acyclovir Triphosphate (ACV-TP), the molecule becomes an inhibitor of the virus's ability to copy its genetic material. ACV-TP works by competitively inhibiting the essential Viral DNA Polymerase enzyme and by being mistakenly incorporated into the growing Viral DNA strand. This incorporation causes irreversible chain termination, immediately terminating the synthesis of new viral genetic material. By permanently halting the virus’s DNA synthesis, the mechanism suppresses the ability of the virus to multiply and produce viable new particles, thereby reducing the accumulation of viral particles and restricting the further propagation of the virus to adjacent, uninfected host cells.

Dosage and Administration Information

Administration Guidelines

Valacyclovir hydrochloride is a prescription antiviral agent used solely by the oral route. It is available as 500 mg and 1 gram tablets, and can be prepared as an extemporaneous oral suspension when a liquid form is necessary. The medicine is designed to be administered without regard to meals and is typically initiated at the earliest sign or symptom of an active viral episode.


Dosing Schedules and Duration

Use of the medicine involves specific, fixed-dose regimens that differ by clinical use. Frequencies include Once Daily (QD) for long-term suppressive therapy in immunocompetent patients, Twice Daily (BID) for recurrent genital herpes and the 1-day cold sore regimen (doses taken 12 hours apart), and Three Times Daily (TID) for the treatment of Herpes Zoster. Treatment courses range from short-term episodes, such as the 1-day course for cold sores or the 3-day course for recurrent genital herpes, to longer courses like the 7-day regimen for shingles. For CMV prophylaxis, the typical administration is Four Times Daily (QID) over a course of approximately 90 days.


Population-Specific Adjustments

Dosage requires reduction or frequency modification for patients with impaired renal function. This adjustment is determined by the patient's calculated creatinine clearance (CrCl) for all indications. Administration in older adults also involves evaluation of renal function for potential dosage adjustment. Furthermore, pediatric dosing for conditions like chickenpox is often determined on a weight-based formula, specified as 20 mg/kg per dose.

Recent Clinical Evidence

Valacyclovir hydrochloride: Recent Clinical Evidence

This section reviews the available research that has evaluated the drug's activity and how studies have explored its potential role in symptom management. The full implications of this research are still being investigated.


Mechanism of Action

Research has focused on understanding the interaction of the compound with a specific enzyme.


Phase I and II Trials

Early clinical trials investigated patient outcomes, with findings exploring the frequency of symptoms. These trials focused primarily on establishing the dose range and identifying potential safety concerns.

  • Phase I: Small studies examined the drug’s kinetics and its initial tolerability profile in healthy volunteers.
  • Phase II: Studies evaluated the drug in a small number of people with the condition to assess tolerability and dose-response relationships.

Key Efficacy Findings (Phase III)

Large-scale Phase III trials evaluated the effect of the drug against a placebo.

  • A study of 500 patients investigated changes in disease activity over a 6-month period.
  • Another key trial examined a secondary outcome measure, finding that studies assessed the use of rescue medication compared to the placebo group.
  • Research evaluated whether this dosage related to the onset of observations.

Safety and Tolerability

The overall safety profile was assessed across all clinical trials. Research noted the frequency of observed events. Studies investigated absorption parameters in relation to meal conditions.

The research examined safety outcomes in subgroups, including participants with liver issues. Studies have not made direct comparisons to older treatments. However, research did examine predefined clinical outcomes.

Key Studies & References

  1. Valacyclovir versus valganciclovir for cytomegalovirus prophylaxis in kidney transplant recipients: a systematic review and comparative meta-analysis (Subgroup safety and efficacy data)

Frequently Asked Questions (FAQ)

Common questions about Valacyclovir hydrochloride (FAQ)

Q: How is Valacyclovir hydrochloride different from other antiviral medicines?

Valacyclovir hydrochloride is classified as a prodrug, which means it is inactive when swallowed. Official product information states it is rapidly converted in the body into the active antiviral component, acyclovir. This specific structure is engineered to result in improved absorption from the gut compared to acyclovir itself.

Q: Does Valacyclovir hydrochloride start working immediately?

According to official sources, the medicine is rapidly absorbed after it is taken by mouth. It is then quickly converted into its active component, acyclovir, by the body’s metabolism. Official guidelines note that therapy is recommended to be initiated at the earliest sign or symptom of a viral episode.

Q: How long does the effect of Valacyclovir hydrochloride last?

Regulatory information indicates the drug itself is present only briefly in the blood. The active component, acyclovir, generally has a plasma half-life of approximately 2.5 to 3.3 hours in adults whose kidney function is normal. This half-life measurement helps determine the appropriate frequency of administration.

Q: Is feeling tired a common side effect of Valacyclovir hydrochloride?

While tiredness, or fatigue, is not listed as one of the most common adverse reactions in all product labeling, it has been noted in reports gathered from patients during post-approval use. Concerns about side effects are generally discussed with a healthcare professional.

Q: Can Valacyclovir hydrochloride affect the kidneys?

Official regulatory documents list Acute Renal Failure as a serious adverse reaction, particularly in certain at-risk patient populations, such as older adults and individuals with existing kidney issues. Patients with reduced kidney function often require a mandatory dosage adjustment.

Q: Are there certain foods or drinks to avoid while taking Valacyclovir hydrochloride?

Official studies indicate that the absorption of the active component is not affected by food or single doses of antacids. Regulatory documents do not list specific foods or drinks that must be avoided when taking this medicine.

Q: What types of prescription medicines should be checked for interactions with Valacyclovir hydrochloride?

Official information details interactions with medicines that compete for the active elimination pathway in the kidneys, such as cimetidine and probenecid, and co-administration with other drugs known to be nephrotoxic (potentially harmful to the kidneys).

Q: Why is Valacyclovir hydrochloride sometimes used for shingles?

The medicine is formally indicated in adults for the treatment of Herpes Zoster, which is commonly known as shingles. This condition is caused by the varicella-zoster virus (VZV), which belongs to the same virus family the drug is designed to manage.

Q: Is Valacyclovir hydrochloride used for general cold sores or only certain types?

Official labeling indicates the medicine is used for the treatment of cold sores (Herpes Labialis) in immunocompetent adults and adolescents 12 years of age and older.

Q: How long after starting Valacyclovir hydrochloride can I expect to see an effect?

Clinical studies emphasize that the medicine is most effective when it is started at the earliest sign or symptom of a viral episode. Depending on the condition being treated, this is generally advised to be within the first one to three days of symptoms appearing.

Q: Does taking Valacyclovir hydrochloride prevent future occurrences?

Regulatory documents state the medicine is formally indicated for chronic suppressive therapy for certain recurrent conditions. This means it is used to help prevent or reduce the frequency of future recurrent episodes in eligible patients.

Q: What is the main benefit of using Valacyclovir hydrochloride compared to older treatments?

Official information confirms that the drug’s molecular structure was engineered to significantly improve its absorption from the digestive tract. This results in enhanced oral bioavailability of the active component, which is a differentiating characteristic compared to the older drug, acyclovir.

Q: Does Valacyclovir hydrochloride treat the underlying cause or just the symptoms?

Official microbiology information confirms that the medicine works by suppressing the virus’s activity. The active component inhibits the virus’s ability to copy its genetic material (DNA synthesis), restricting the further multiplication and spread of the virus.

Q: Is Valacyclovir hydrochloride typically used for initial or recurring outbreaks?

The medicine is formally indicated for the treatment of both initial episodes and recurrent episodes of genital herpes in adults. It is also indicated for chronic suppressive therapy to reduce the frequency of future recurrences.

Q: Are there any common interactions with over-the-counter pain relievers?

While no specific over-the-counter pain relievers are named, official documents caution against co-administration with other nephrotoxic drugs (drugs that can be harmful to the kidneys). This potential risk is noted to be greater in older adults or individuals with underlying kidney impairment.

Q: Can I use Valacyclovir hydrochloride if I have liver problems?

Official documents indicate that no specific dosage adjustment is generally needed for patients with mild-to-moderate liver disease. However, as is standard practice, clinical review and caution are advised for patients with existing liver issues.

Q: How does the body process Valacyclovir hydrochloride?

Following oral administration, the prodrug is quickly absorbed and converted by enzymes in the intestine and liver into its active form, acyclovir. This active form is then primarily eliminated from the body through the kidneys.

Q: Are there any foods that can reduce the absorption of Valacyclovir hydrochloride?

Official product information states that clinical studies found that the absorption of the active component is not altered when the medicine is taken with food.

Q: What is the half-life of Valacyclovir hydrochloride according to official documents?

The half-life refers to the time it takes for the concentration of a substance in the body to be reduced by half. The active component, acyclovir, has a mean plasma half-life of 2.5 to 3.3 hours in adults with normal kidney function, as documented in official prescribing information.

Q: Is Valacyclovir hydrochloride mentioned in research for preventing transmission?

Yes, regulatory documents indicate the medicine is formally approved for the reduction of transmission of genital herpes. This indication applies to patients who do not have HIV and who are in a relationship with a partner who does not have the infection.

Q: What is the chemical name for Valacyclovir hydrochloride?

According to official descriptions, Valacyclovir hydrochloride is the hydrochloride salt of the L-valyl ester of acyclovir.

Q: Can Valacyclovir hydrochloride interact with herbal supplements like St. John's Wort?

Official interaction tables do not specifically list St. John's Wort. Regulatory documents note that patients should review all medicines and supplements, including herbal products, with a healthcare professional.

Q: Is Valacyclovir hydrochloride considered a first-line treatment for its primary uses?

Clinical reviews and official information consistently note that this medicine, due to its enhanced absorption, is described in clinical reviews as a first-line treatment option for many patients dealing with herpesvirus infections.

Q: Is there research evidence regarding the long-term use of Valacyclovir hydrochloride?

The efficacy and safety of using the medicine for the suppression of recurrent genital herpes have been established for up to 1 year in patients with normal immune function and for up to 6 months in HIV-infected patients, according to official labeling.

Q: Can people with a known history of kidney issues use Valacyclovir hydrochloride?

Use in patients with kidney issues is possible, provided that specific dosage adjustments are made. Official prescribing information states that patients with impaired renal function require a mandatory reduction or adjustment to the dosing frequency. This is a critical step to reduce the heightened risk of serious adverse reactions in this group.

Q: Does Valacyclovir hydrochloride affect birth control pills?

Official sources have not documented a clinically significant drug interaction between valacyclovir hydrochloride and common hormonal contraceptives (birth control pills).

Q: Why is it important to stay hydrated when taking Valacyclovir hydrochloride?

Official documents advise maintaining adequate fluid intake. This guidance is given because there is a documented risk of acute renal failure, particularly when dehydrated, and proper hydration is recommended to help the kidneys function correctly.

Q: Are blood tests generally required while using Valacyclovir hydrochloride?

A blood test is required to calculate creatinine clearance, which is essential to assess kidney function. This assessment is mandatory for determining the appropriate dosage for patients with impaired kidney function. Blood tests may also be used to monitor for suspected liver abnormalities.

Q: Are there any warnings about driving or operating machinery while taking Valacyclovir hydrochloride?

Official patient information notes that adverse reactions such as dizziness, confusion, or other Central Nervous System (CNS) effects may occur. Official information indicates that if these side effects occur, activities requiring mental alertness, such as driving or operating machinery, should be avoided.

Q: What is the difference in action between Valacyclovir hydrochloride and a topical cream?

Valacyclovir hydrochloride works systemically (from within the body) by having its active component inhibit the virus's ability to copy its genetic material. Topical creams typically act locally on the skin surface to manage symptoms.

How should Valacyclovir hydrochloride be stored and disposed of?

Storage and Handling Requirements

Valacyclovir hydrochloride tablets must be stored at controlled room temperature, specifically maintained between 15 C and 25 C (59 F and 77 F). The medication must be kept in the container it came in, and this container should be tightly closed to protect the product from excess heat and moisture.

Formulation Required Temperature Special Conditions
Tablets Room Temperature Keep away from heat and moisture
Prepared Suspension Refrigerated (2 C to 8 C) Discard after 14-28 days

For child safety, the tablets and all medicines must be stored out of the reach of children.

Disposal

Expired or unused valacyclovir hydrochloride must be discarded by following FDA guidelines or local regulations for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valacyclovir hydrochloride found in:

A-Z Index: